Effects of pioglitazone and linagliptin on glycemic control, lipid profile and hs-CRP in metformin-treated patients with type 2 diabetes: a comparative study.

IF 1.1 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Hormone Molecular Biology and Clinical Investigation Pub Date : 2023-12-26 eCollection Date: 2023-12-01 DOI:10.1515/hmbci-2022-0070

Batool Zamani, Seyyed Mashaalah Tabatabizadeh, Hamidreza Gilasi, Shadi Yazdani

{"title":"Effects of pioglitazone and linagliptin on glycemic control, lipid profile and hs-CRP in metformin-treated patients with type 2 diabetes: a comparative study.","authors":"Batool Zamani, Seyyed Mashaalah Tabatabizadeh, Hamidreza Gilasi, Shadi Yazdani","doi":"10.1515/hmbci-2022-0070","DOIUrl":null,"url":null,"abstract":"Objectives: The purpose of this study was to compare the effects of pioglitazone and linagliptin on glycemic control, lipid profile and high-sensitivity C-reactive protein (hs-CRP) parameters in patients with type 2 diabetes treated with metformin.Methods: The present randomized clinical trial was conducted on 60 patients with type 2 diabetes treated with metformin in the age range of 30-60 years. The participants with informed consent were randomly assigned to receive pioglitazone or linagliptin. The first intervention group (n=30) received 30 mg of pioglitazone daily and the second intervention group (n=30) received 5 mg of linagliptin daily for 12 weeks. Fasting blood samples were taken from patients at the baseline and after 12 weeks to measure related variables. The current study was approved in Kashan University of Medical Sciences (with the code of ethics of IR.KAUMS.MEDNT.REC.1398.016), and the Iranian Registry of Clinical Trials (with the registration number of IRCT20170513033941N66).Results: The linagliptin administration significantly reduced serum levels of fasting blood sugar (p=0.03), blood sugar 2 h after a meal (p=0.02), glycosylated hemoglobin (p=0.02) and hs-CRP (p=0.005) after 12 weeks compared with pioglitazone. In contrast, the pioglitazone administration significantly decreased triglyceride levels (p=0.01) and increased HDL-cholesterol (p=0.002) compared to linagliptin. In addition, the administration of both linagliptin and pioglitazone drugs had no significant effect on LDL-cholesterol, total cholesterol, systolic and diastolic blood pressure, creatinine and blood urea.Conclusions: The present study demonstrated the superiority of linagliptin over pioglitazone for glycemic control, although pioglitazone compared to linagliptin showed greater efficacy in reducing triglycerides and raising HDL-cholesterol.","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2022-0070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The purpose of this study was to compare the effects of pioglitazone and linagliptin on glycemic control, lipid profile and high-sensitivity C-reactive protein (hs-CRP) parameters in patients with type 2 diabetes treated with metformin.

Methods: The present randomized clinical trial was conducted on 60 patients with type 2 diabetes treated with metformin in the age range of 30-60 years. The participants with informed consent were randomly assigned to receive pioglitazone or linagliptin. The first intervention group (n=30) received 30 mg of pioglitazone daily and the second intervention group (n=30) received 5 mg of linagliptin daily for 12 weeks. Fasting blood samples were taken from patients at the baseline and after 12 weeks to measure related variables. The current study was approved in Kashan University of Medical Sciences (with the code of ethics of IR.KAUMS.MEDNT.REC.1398.016), and the Iranian Registry of Clinical Trials (with the registration number of IRCT20170513033941N66).

Results: The linagliptin administration significantly reduced serum levels of fasting blood sugar (p=0.03), blood sugar 2 h after a meal (p=0.02), glycosylated hemoglobin (p=0.02) and hs-CRP (p=0.005) after 12 weeks compared with pioglitazone. In contrast, the pioglitazone administration significantly decreased triglyceride levels (p=0.01) and increased HDL-cholesterol (p=0.002) compared to linagliptin. In addition, the administration of both linagliptin and pioglitazone drugs had no significant effect on LDL-cholesterol, total cholesterol, systolic and diastolic blood pressure, creatinine and blood urea.

Conclusions: The present study demonstrated the superiority of linagliptin over pioglitazone for glycemic control, although pioglitazone compared to linagliptin showed greater efficacy in reducing triglycerides and raising HDL-cholesterol.

查看原文本刊更多论文

吡格列酮和利拉利汀对二甲双胍治疗的 2 型糖尿病患者血糖控制、血脂状况和 hs-CRP 的影响：一项比较研究。

研究目的本研究旨在比较吡格列酮和利拉利汀对二甲双胍治疗的2型糖尿病患者血糖控制、血脂状况和高敏C反应蛋白（hs-CRP）参数的影响：本随机临床试验的对象是 60 名接受二甲双胍治疗的 2 型糖尿病患者，年龄在 30-60 岁之间。获得知情同意的参与者被随机分配接受吡格列酮或利拉利汀治疗。第一干预组（30 人）每天服用 30 毫克吡格列酮，第二干预组（30 人）每天服用 5 毫克利拉利汀，为期 12 周。在基线和 12 周后分别采集患者的空腹血样，以测量相关变量。本研究获得了卡尚医科大学（伦理守则为 IR.KAUMS.MEDNT.REC.1398.016）和伊朗临床试验登记处（登记号为 IRCT20170513033941N66）的批准：结果：与吡格列酮相比，12周后服用利拉利汀可显著降低血清中的空腹血糖水平（p=0.03）、餐后2小时血糖水平（p=0.02）、糖化血红蛋白水平（p=0.02）和hs-CRP水平（p=0.005）。相反，与利拉利汀相比，服用吡格列酮可显著降低甘油三酯水平（p=0.01），提高高密度脂蛋白胆固醇（p=0.002）。此外，服用利拉利汀和吡格列酮对低密度脂蛋白胆固醇、总胆固醇、收缩压和舒张压、肌酐和血尿素均无明显影响：本研究表明，在控制血糖方面，利拉利汀优于吡格列酮，但与利拉利汀相比，吡格列酮在降低甘油三酯和提高高密度脂蛋白胆固醇方面的疗效更好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hormone Molecular Biology and Clinical Investigation BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

2.60

自引率

0.00%

发文量

期刊介绍： Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.